BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Syndax is a late stage oncology company whose lead product candidate is entinostat, an oral, selective histone deacetylase inhibitor (HDACi) that is being developed to treat therapy-resistant cancers through an epigenetic mechanism. Entinostat was recently granted Breakthrough Therapy designation by the FDA based on data from the company's completed Phase 2b clinical trial for ER+ metastatic breast cancer.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.